Commercialization of nanotechnologies in Russian Health Care System RHCS requires detail analysis of all obstacles. Here we discuss 3 problems: Prof. Ilizarov’s apparatus; ‘Perftorun’, known as ‘blue blood’ therapy of Russian prof. Beloyartsev; ‘Litar’ and artificial bone technology of Prof. Krasnov, used to replace bones defects. We look into challenges of Russian nanotechnology clusters and education. Prof. Petrov, coauthor of our communication, has his own rich experience in implementing new nanotechnologies, used to treat injured military personnel in Russian armed conflicts, such as Chechen war.
Russian technology innovations require 30 - 40 years for commercialization, 5 - 10 years in USA . Substantial investment capital significant stringent requirements and high chance of technology failure in preclinical or clinical trials hinder this development in developed countries. Stringent regulatory approval state process further increases time and cost its moving to the market. Patent protection is often key strategy to attract multimillion investment required for early stage transition of medical technology into commercial product.
Our proposal is to enhance commercial translation of 3 above mentioned organizations. Then enable treatment of severe bone fractures and injuries, where patient’s own tissues cannot be employed. These technologies were validated through surgical procedure performed in military. RHCS authorities are evaluated based on how efficiently they conduct certification and regulatory approval of new medical technologies.